Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
The insurer reported higher operating earnings, citing an improved medical cost ratio, while warning that costs are still elevated.
THE APEX TIMES
THE APEX TIMES
A new round of analyst updates is nudging UnitedHealth Group’s perceived fair value higher, with estimates rising to about $424 from roughly $411 previously, according to a market update published on July 16, 2026.
THE APEX TIMES
Healthcare insurer UnitedHealth rallied sharply after reporting results that beat expectations, even as semiconductor-linked weakness weighed on Nasdaq-related sentiment before the market open.
THE APEX TIMES
UnitedHealth reported better-than-expected Q2 CY2026 revenue, even as sales were flat year over year at $112 billion. The company also posted non-GAAP earnings of $6.38 per share.
THE APEX TIMES
AtaiBeckley surged about 50% ahead of the open after a market report said Eli Lilly is in talks to buy the psychedelic-focused company at a premium. Neither company confirmed the negotiations in the posting that circulated to markets.
THE APEX TIMES
Shares of the psychedelics-focused biotech AtaiBeckley surged in premarket trading after reports that Eli Lilly is in discussions about a potential deal, sending momentum into a space that has attracted both scientific and commercial interest.
THE APEX TIMES
Shares of GH Research (NASDAQ: GHRS) rose sharply in early trading after media reports said Eli Lilly (NYSE: LLY) is discussing an acquisition of psychedelic drug developer Atai Life Sciences (NASDAQ: ATAI). No companies involved confirmed the discussions in the report.
THE APEX TIMES
The largest U.S. health insurer posted results that beat market expectations for its second quarter and increased its full-year guidance, according to a report published by Yahoo Finance.
THE APEX TIMES
The Cambridge biotech said the first participant has received doses in its Phase 1 study evaluating mRNA-4200, an investigational mRNA-based treatment designed to target cancer antigens in solid tumors.
